Related Experiment Video

Updated: Dec 7, 2025

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

4.1K

Receptor Tyrosine Kinases in Osteosarcoma Treatment: Which Is the Key Target?

Zhichao Tian1, Xiaohui Niu2, Weitao Yao1

  • 1Department of Orthopedics, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.

Frontiers in Oncology
|September 28, 2020
PubMed

Insights

Multi-target tyrosine kinase inhibitors (TKIs) show promise for osteosarcoma treatment. Simultaneous inhibition of key targets like VEGFRs and RET is crucial for therapeutic breakthroughs.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Multi-target tyrosine kinase inhibitors (TKIs) are increasingly studied for osteosarcoma treatment.
  • The specific targets responsible for the therapeutic efficacy of these TKIs remain unclear.

Purpose of the Study:

  • To review TKIs evaluated in clinical trials for osteosarcoma.
  • To compare and discuss the targets of these TKIs to identify key therapeutic targets.

Main Methods:

  • Systematic review of TKIs from clinical trials registered on ClinicalTrials.gov.
  • Comparative analysis of TKI targets and their correlation with therapeutic effects.

Main Results:

  • Apatinib, cabozantinib, lenvatinib, regorafenib, and sorafenib demonstrated promising therapeutic effects.
  • Vascular Endothelial Growth Factor Receptors (VEGFRs) and RET emerged as potential key targets.
  • Other receptor tyrosine kinases (RTKs) like MET, IGF-1R, AXL, PDGFRs, KIT, and FGFRs appear less critical.

Conclusions:

  • Single RTK inhibition is insufficient for effective osteosarcoma treatment.
  • Simultaneous inhibition of multiple relevant RTKs is necessary for therapeutic advancement.
  • This review offers valuable insights into TKI targets for future osteosarcoma research.
Keywords:
RETRTKsTKIsVEGFRsosteosarcomatarget therapy

More Related Videos

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models04:25

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

10.8K
Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

7.5K

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.4K
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
16.9K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.6K
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
84.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K